Cheapest Wegovy Dosing Chart - UK Price From £69.00

Our Pricing

Wegovy Dosing Chart & Online Prescription Service

Published on: June 03, 2026

Understanding the wegovy dosing chart uk online is essential before starting semaglutide treatment for weight management. At Cured Pharmacy, our UK-registered clinical team provides transparent dosing guidance alongside your free online consultation, with genuine Wegovy pens from £79.00 and discreet next-day delivery across the UK.

Complete Wegovy Dose Escalation Schedule

Wegovy follows a structured five-month dose escalation protocol designed to minimise gastrointestinal side effects whilst optimising weight loss outcomes [1]. Each pen delivers a fixed weekly dose, and your UK prescriber will guide you through the entire schedule during your clinical assessment.

The standard Wegovy dosing chart begins at 0.25mg weekly for month one, increasing to 0.5mg in month two, 1mg in month three, 1.7mg in month four, and reaching the maintenance dose of 2.4mg from month five onwards [1]. This gradual titration allows your body to adapt to semaglutide's effects on GLP-1 receptors, which regulate appetite and gastric emptying.

Clinical data from the STEP trials demonstrated that patients following this precise escalation schedule achieved an average 14.9% body weight reduction over 68 weeks, compared to 2.4% with placebo [2]. The dose escalation is not optional — skipping steps or accelerating the schedule may increase the risk of nausea, vomiting, and treatment discontinuation.

What Happens If You Miss a Dose

If you miss a Wegovy injection and fewer than five days have passed since your scheduled dose, administer it as soon as you remember. If more than five days have elapsed, skip the missed dose entirely and resume your regular weekly schedule [1]. Never double up doses to compensate for missed injections, as this significantly increases the risk of adverse gastrointestinal effects.

How Wegovy Semaglutide Works for Weight Loss

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics a natural hormone your intestines produce after eating [2]. When administered subcutaneously once weekly, semaglutide activates GLP-1 receptors in the brain's appetite regulation centres, reducing hunger signals and increasing feelings of fullness.

Unlike older weight loss medications that work peripherally, semaglutide crosses into the central nervous system to directly influence hypothalamic circuits controlling food intake [3]. This central mechanism explains why patients report genuine reduction in food cravings rather than simply feeling restricted — the medication fundamentally alters appetite perception at a neurological level.

Semaglutide also slows gastric emptying, meaning food remains in your stomach longer after meals, which prolongs satiety [3]. The combination of reduced appetite, enhanced fullness, and delayed gastric emptying creates multiple complementary pathways for sustained weight reduction when combined with lifestyle modifications.

Wegovy Dosing Chart: Month-by-Month Breakdown

Month one (weeks 1-4): 0.25mg weekly. This introductory dose allows your body to begin adapting to GLP-1 receptor activation. Most patients experience minimal side effects at this strength, though mild nausea may occur initially [1].

Month two (weeks 5-8): 0.5mg weekly. The dose doubles, and appetite suppression becomes more noticeable. This is typically when patients begin reporting reduced portion sizes and fewer between-meal cravings.

Month three (weeks 9-12): 1mg weekly. At this therapeutic threshold, clinical trials showed measurable weight loss acceleration. Your UK prescriber will review your progress and tolerability before approving this escalation [2].

Month four (weeks 13-16): 1.7mg weekly. This penultimate dose approaches full therapeutic strength. Gastrointestinal adaptation should be well-established by this stage, though some patients experience transient nausea when first increasing to 1.7mg.

Month five onwards (week 17+): 2.4mg weekly maintenance dose. This is the target strength used in all major STEP trials, where maximum weight loss outcomes were demonstrated [2]. You'll remain on 2.4mg weekly for as long as clinically appropriate, subject to ongoing prescriber review.

Can You Stay on a Lower Dose

Some patients achieve their weight management goals on sub-maintenance doses like 1mg or 1.7mg weekly. Your UK prescriber may approve remaining at a lower strength if you're experiencing excellent results with minimal side effects, though the 2.4mg dose produced superior outcomes in clinical trials [2]. Dosing decisions must always be individualised based on your response, tolerability, and clinical circumstances.

Wegovy vs Other Weight Loss Injections: Dosing Differences

Whilst Wegovy uses a five-month escalation to 2.4mg weekly, Saxenda (liraglutide) requires daily injections titrated over five weeks to 3mg daily [4]. The daily administration burden makes Saxenda less convenient for many patients, though it remains a licensed option for those who prefer shorter-acting GLP-1 therapy.

Mounjaro (tirzepatide) follows a different escalation schedule entirely, starting at 2.5mg weekly and potentially increasing to 15mg weekly over several months [5]. Tirzepatide is a dual GIP/GLP-1 receptor agonist, offering a distinct mechanism compared to Wegovy's single-pathway GLP-1 action. In head-to-head trials, tirzepatide produced greater average weight loss than semaglutide, though both medications demonstrate significant efficacy [5].

Your choice between these treatments depends on multiple factors including your medical history, previous weight loss attempts, injection frequency preference, and cost considerations. Our UK clinical team will discuss all licensed options during your free online consultation to identify the most appropriate therapy for your individual circumstances.

Common Side Effects During Dose Escalation

Gastrointestinal side effects are most common during the first eight weeks of Wegovy treatment and typically when escalating to each new dose strength [2]. Nausea affects approximately 44% of patients in clinical trials, though severity is usually mild to moderate and diminishes over time as your body adapts to each dose level.

Other frequently reported side effects include diarrhoea (30% of patients), constipation (24%), vomiting (24%), and abdominal pain (20%) [2]. These effects are generally transient, peaking within the first few days after dose escalation and resolving within one to two weeks. Eating smaller meals, avoiding high-fat foods, and staying well-hydrated can help minimise gastrointestinal discomfort.

Serious side effects are rare but require immediate medical attention. Contact your GP or NHS 111 if you experience severe persistent abdominal pain (which may indicate pancreatitis), visual changes, signs of thyroid swelling, or symptoms of gallbladder disease [1]. Your Cured Pharmacy prescriber will review your full medical history during consultation to identify any contraindications before prescribing Wegovy.

Managing Nausea During Treatment

To reduce nausea, eat slowly and stop when comfortably full rather than completely full. Choose bland, low-fat foods during the first few days after each dose increase, and avoid lying down immediately after meals. Ginger tea and small frequent meals throughout the day may help settle your stomach. If nausea persists beyond two weeks at any dose level, contact your prescriber to discuss whether temporarily remaining at your current dose is appropriate before attempting further escalation.

Getting Your Wegovy Prescription Online at Cured Pharmacy

Our online consultation takes under three minutes and covers your medical history, current medications, weight management goals, and any contraindications to semaglutide therapy. You'll be assessed by a UK-registered prescriber (not an algorithm), who will determine whether Wegovy is clinically appropriate and which starting dose is suitable for your circumstances.

If approved, your prescription is sent directly to our UK-registered pharmacy (GPhC 9012511) where Superintendent Pharmacist Tarun Kumar (GPhC 2233073) and his team dispense genuine UK-licensed Wegovy pens. We offer discreet next-day delivery in plain packaging, with no branding visible on the exterior. You'll receive your first month's supply with clear written instructions on injection technique and the dose escalation schedule.

Pricing is transparent before you begin the consultation. Wegovy starts from £79.00 at Cured Pharmacy, with the exact cost depending on your prescribed dose strength. There are no hidden fees — the price you see includes the medication, clinical consultation, and delivery. Ongoing prescriptions require periodic clinical review to ensure the treatment remains safe and effective for your individual needs.

Who Can Use Wegovy in the UK

Wegovy is licensed in the UK for adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidaemia [1]. Your prescriber will calculate your BMI during the consultation and assess whether you meet the clinical criteria. Wegovy is not suitable for pregnant or breastfeeding women, anyone with a personal or family history of medullary thyroid carcinoma, or patients with multiple endocrine neoplasia syndrome type 2.

Scientific References

1. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. Retrieved from https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Müller, T. D., et al. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72–130. https://doi.org/10.1016/j.molmet.2019.09.010 [accessed 13 August 2026]
4. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
5. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.